Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 93

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 93
---
Medical Device Regulation qualification and scaleup); |

| ● | approximately $1.1 million for                                                                                                            
 the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the December 2024 Loan Agreement 
 and accrued interest and applicable risk premium;                                                                                         |

| ● | $0.25 million to be paid to the Chairman of our                                                                                  
 board of directors in consideration of his services to the Company since 2019, for which he has not received compensation, which 
 was approved by our shareholders on March 20, 2025;                                                                              |

| ● | $0.43 million                                             
 for payment of the CSL Settlement (as defined below); and |

| ● | the remainder for working capital and general corporate 
 purposes and possible future acquisitions.              |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate
with certainty the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone
basis. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization
efforts, regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will
not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds
from this offering. For additional information regarding the repayment of the Bridge Loan, see “Certain Relationships and Related
Party Transactions – Other Financings.”

Based on our current plans,
we believe that our existing cash, cash equivalents and short-term deposits, will be sufficient to enable us to fund our operating expenses
and capital expenditure requirements through October 31, 2025. We anticipate that these funds, together with the net proceeds of this
offering, will be sufficient to fund our operating expenses and capital expenditure requirements through March 31, 2027, including the
completion of our pivotal trial for GelrinC with the two-year follow-up required by the FDA. We have based this estimate on assumptions
that may prove to be incorrect, and we could use our available capital resources sooner than we